arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

Zymeworks Inc.

ZYME
$23.52 ▲ +0.34 (+1.47%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
23 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
17
Health
Poor
Bearish
auto_awesome

Analytical Summary

Zymeworks Inc. faces fundamental challenges with weakness in Return on Common Equity (%) and Profit Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $1.8B
Dividend Yield
Revenue Growth -91.1%
Op. Margin None
ROIC -27.4%
FCF / Share $-0.62
Trailing P/E
Price / Book 10.5x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

23-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.41M
↓ -91.1%
Net Income Profit after all expenses
$-44.16M
↓ -95.1%
Operating Margin Operating profit as % of sales
-80.1%
↓ -5688.4% 3th
FCF / Share Free cash flow per share
$-0.62
↓ -1250.9%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability
4
Returns
23
Cash Quality
37

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 7 years · 23 quarters